Asset Details
Do you wish to reserve the book?
The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease
Do you wish to request the book?
The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease
2014
Overview
Background
In Coats’ disease, the most recent development in the treatment has been the intravitreal injection of anti-VEGF agents. The purpose of this article was to evaluate the effect of intravitreal bevacizumab as the initial treatment for Coats’ disease in children and adults.
Methods
The study included 14 pediatric patients and five adult patients with Coats’ disease. They were treated with intravitreal bevacizumab (1.25 mg/0.05 ml) as the initial treatment, combined with or without other treatments. The analyses included the evaluation of basic clinical conditions.
Results
In the pediatric group, after a mean of 9.1 months of follow-up, the differences in visual acuity were significant for the comparisons between the baseline examination and the follow-up examinations carried out at weeks 6, 12, and 24 after the baseline (
P
= 0.006,
P
= 0.004,
P
= 0.005 respectively). Vitreoretinal fibrosis was observed in three patients (
n
= 3, 21.4 %), among whom two showed fibrosis before treatment. All of the pediatric patients showed a resolution of fluid and exudation, and regression of the telangiectasia. In the adult group, after a mean of 10.6 months of follow-up, the differences in visual acuity were not statistically significant (
P
> 0.05) between the baseline and follow-up examinations. Vitreoretinal fibrosis (
n
= 2, 40 %) was observed in two patients who both showed fibrosis before treatment. All of the adult patients showed a resolution of fluid and exudation, and regression of the telangiectasia. The differences in the change of BCVA between children and adults were not significant (
P
> 0.05) during the follow-up examinations.
Conclusion
The intravitreal injection of bevacizumab as the initial treatment is associated with a measurable gain in visual acuity in patients with Coats’ disease. Resolution of the subretinal fluid and exudation, and regression of the telangiectasia were observed in both pediatric and adult patients. Vitreoretinal fibrosis may be one of the natural courses of Coats’ disease, and it remains uncertain whether bevacizumab accelerates the fibrosis phenomenon.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Angiogenesis Inhibitors - therapeutic use
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Child
/ Female
/ Fibrosis
/ Humans
/ Male
/ Medicine
/ Retinal Telangiectasis - diagnosis
/ Retinal Telangiectasis - drug therapy
/ Tomography, Optical Coherence
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
